Report Highlights

Smart Contact Lenses in the U.S.: Market Overview

The U.S. smart contact lens market was valued at USD 48 million in 2024 and is forecast to reach USD 209 million by 2032, a 20.2% compound annual growth rate. Commercial activity is concentrated in sensor-based lenses for intraocular pressure monitoring, the segment closest to market release, while display and glucose-sensing devices remain in clinical development. Every product reaching U.S. patients passes through FDA premarket review, which makes regulatory clearance, rather than consumer demand, the binding constraint on market entry.

Government has shaped the market's structure more than private capital at this early stage. The National Eye Institute within the National Institutes of Health and the Department of Veterans Affairs Office of Research and Development have funded ocular sensing and visual prosthetic research, setting the technical pathways that reach clinical trials. Private firms then carry commercialisation: California-based Mojo Vision has led display development, while Alcon and Johnson & Johnson Vision enter mainly through acquisition and licensing agreements.

Policy-Driven Growth in U.S. Smart Contact Lenses

Section 515B of the Federal Food, Drug, and Cosmetic Act, added by the FDA Safety and Innovation Act of 2012, underpins the Breakthrough Devices Program, which grants priority FDA interaction to devices treating life-threatening or irreversibly debilitating conditions. Sensing lenses targeting glaucoma, which causes irreversible vision loss, fit this criterion and can secure designation. Under MDUFA V, covering fiscal years 2023 to 2027, FDA committed to 180-day review goals for most original premarket approval submissions, converting clinical data into revenue faster.

The Centers for Medicare and Medicaid Services finalised its Transitional Coverage for Emerging Technologies notice in August 2024, allowing up to five Breakthrough devices per year to receive Medicare coverage with evidence development. This closes a reimbursement gap, because smart lenses have no dedicated HCPCS code within the V2500–V2599 contact lens series. Coverage under this pathway converts clinical adoption into recurring Medicare Part B revenue for sensing lens manufacturers.

Regulatory Barriers and Compliance Costs

The Federal Communications Commission administers equipment authorization under 47 CFR Part 15 Subpart C, which applies to any lens containing a Bluetooth Low Energy transmitter. Developers must complete FCC certification before retail sale, and accredited testing typically adds three to six months and tens of thousands of dollars. FDA user fees add further cost, as standard premarket approval application fees exceeded USD 500,000 in FY2025, while the Quality Management System Regulation under 21 CFR Part 820 aligns quality systems with ISO 13485.

Data governance creates the second barrier. The Federal Trade Commission's Health Breach Notification Rule, 16 CFR Part 318, as amended effective July 2024, requires breach notification from non-HIPAA entities, which covers most companion apps. The Illinois Biometric Information Privacy Act requires written consent before collecting retina or iris scans, enforced through private litigation carrying statutory damages. Section 524B of the FD&C Act also requires cybersecurity plans in premarket submissions for cyber devices.

Policy-Created Opportunities in U.S. Smart Contact Lenses

Medicare coverage for glaucoma management creates the first commercial opening. Intraocular pressure is the core diagnostic metric in glaucoma care, and a TCET-covered sensing lens that replaces repeated clinic tonometry visits would fit within existing Medicare Part B diagnostic billing. Developers securing Breakthrough designation for glaucoma sensing lenses gain first access to this channel, ahead of consumer-facing products.

Federal procurement offers the second opening. The Veterans Health Administration purchases ophthalmic devices through the Federal Supply Schedule, providing predictable multi-year contracts for vendors. The Department of Defense Military Health System also procures ophthalmic care for active-duty personnel, creating volume demand for low-vision assistive devices that smart lenses can address.

Market at a Glance

Leading Market Participants

• Alcon
• Johnson & Johnson Vision
• Bausch + Lomb
• CooperVision
• Mojo Vision
• Verily Life Sciences
• Sensimed
• Innovega
• Ocumetics Technology
• Samsung Electronics

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, Chapter V, which the Medical Device Amendments of 1976 established as the framework for device classification and premarket review. FDA's Center for Devices and Radiological Health administers smart lens applications, requiring premarket approval under 21 CFR Part 814 for higher-risk sensing designs and an Investigational Device Exemption under 21 CFR Part 812 for clinical trials. Quality systems must comply with 21 CFR Part 820, effective February 2, 2026.

Key changes carry fixed dates. MDUFA VI negotiations between FDA and industry run through 2026, and reauthorisation must pass before September 30, 2027. Section 524B cybersecurity requirements have applied to premarket submissions since March 2023. Compared with regional peers, the U.S. route is faster than the EU Medical Device Regulation, Regulation (EU) 2017/745, which requires notified-body certification for comparable devices.

Long-Term Policy Outlook for U.S. Smart Contact Lenses

By 2032, MDUFA VI will reset review commitments and user fees for the next reauthorisation cycle. FDA's final guidance on predetermined change control plans, issued in December 2024, allows AI-enabled devices to update algorithms under pre-approved protocols. Smart lens firmware updates will therefore move without fresh submissions, reducing iteration costs for manufacturers.

Reimbursement and privacy will reshape commercial structure. TCET's first coverage decisions will set the template for Medicare payment for sensing lenses, expanding from glaucoma into diabetes-related monitoring by 2032. State privacy statutes, including the California Consumer Privacy Act as amended by the California Privacy Rights Act, will require consumer manufacturers to adopt data governance programmes comparable to clinical-grade systems.